Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 720 participants.
Also called NCT01644188
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 720 participants
- Sponsor
- Registry
-
NCT01644188 -
2011-004130-34
-
- Other papers using this trial's data
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Denmark, France, Hungary, Israel, Russia, South Africa, South Korea, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01644188. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-11-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebo (for ezetimibe)
- Intervention (Drug)
- Lipid Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01644188- Content hash
57ae53bf9839fbbc6c87604a80f38263a5514d8e3fe05c0ac73618abbf5deb39